Conversely, the AMPK agonist increased mitochondrial damage and MPT, reduced LDH activity levels and the proportion of PI‐positive cells, inhibited iron concentration levels, and expanded GSH and GPX4 protein expressions in NSCLC with downregulated TRIM11 gene expression (as depicted in Figure 6H–N). The gene discussed is GPX4; the disease is non-small cell lung carcinoma.